Contrary to melanoma however, the mutational burden of sarcomas is low, the numbers of TILs in the tumour microenvironment are low and the PD-L1+ expression is significantly lower, which may explain the variable responses documented with different immune checkpoint inhibitors. This evidence concerns the gene CD274 and neoplasm.